Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment.

Pieper N, Zaremba A, Leonardelli S, Harbers FN, Schwamborn M, Lübcke S, Schrörs B, Baingo J, Schramm A, Haferkamp S, Seifert U, Sucker A, Lennerz V, Wölfel T, Schadendorf D, Schilling B, Paschen A, Zhao F.

Oncoimmunology. 2018 Apr 18;7(8):e1450127. doi: 10.1080/2162402X.2018.1450127. eCollection 2018.

PMID:
30221038
2.

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance.

Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A.

J Natl Cancer Inst. 2018 Jun 1;110(6):677-681. doi: 10.1093/jnci/djx271.

PMID:
29917141
3.

Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling.

Griewank KG, Koelsche C, van de Nes JAP, Schrimpf D, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Murali R, Pietsch T, von Deimling A, Schadendorf D.

Clin Cancer Res. 2018 Sep 15;24(18):4494-4504. doi: 10.1158/1078-0432.CCR-18-0763. Epub 2018 Jun 11.

PMID:
29891723
4.

Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma.

Bezrookove V, Nosrati M, Miller JR 3rd, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE, Davies MA, Schadendorf D, Kashani-Sabet M.

Clin Cancer Res. 2018 Sep 1;24(17):4119-4125. doi: 10.1158/1078-0432.CCR-18-0791. Epub 2018 May 18.

PMID:
29776954
5.

NF1 mutations in conjunctival melanoma.

Scholz SL, Cosgarea I, Süßkind D, Murali R, Möller I, Reis H, Leonardelli S, Schilling B, Schimming T, Hadaschik E, Franklin C, Paschen A, Sucker A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Br J Cancer. 2018 May;118(9):1243-1247. doi: 10.1038/s41416-018-0046-5. Epub 2018 Mar 21.

PMID:
29559732
6.

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.

Machiraju D, Moll I, Gebhardt C, Sucker A, Buder-Bakhaya K, Schadendorf D, Hassel JC.

Melanoma Res. 2018 Jun;28(3):204-210. doi: 10.1097/CMR.0000000000000435.

PMID:
29485532
7.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M.

Clin Chem. 2018 May;64(5):830-842. doi: 10.1373/clinchem.2017.281543. Epub 2018 Feb 26.

PMID:
29483107
8.

Intraventricular melanocytoma diagnosis confirmed by gene mutation profile.

Knappe UJ, Tischoff I, Tannapfel A, Reinbold WD, Möller I, Sucker A, Schadendorf D, Griewank KG, van de Nes JAP.

Neuropathology. 2018 Jun;38(3):288-292. doi: 10.1111/neup.12443. Epub 2017 Dec 11.

PMID:
29226425
9.

PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.

Schaper-Gerhardt K, Okoye S, Herbst R, Ulrich J, Terheyden P, Pföhler C, Utikal JS, Kreuter A, Mohr P, Dippel E, Satzger I, Sucker A, Schadendorf D, Ugurel S, Gutzmer R.

Eur J Cancer. 2018 Jan;88:67-76. doi: 10.1016/j.ejca.2017.10.026. Epub 2017 Nov 28.

PMID:
29195116
10.

Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.

Griewank KG, Wiesner T, Murali R, Pischler C, Müller H, Koelsche C, Möller I, Franklin C, Cosgarea I, Sucker A, Schadendorf D, Schaller J, Horn S, Brenn T, Mentzel T.

Mod Pathol. 2018 Mar;31(3):418-428. doi: 10.1038/modpathol.2017.146. Epub 2017 Nov 3.

PMID:
29099504
11.

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Ugurel S, Kiecker F, Fröhling S, Wetter A, Bankfalvi A, Sucker A, Zimmer L, Livingstone E, Roesch A, Becker JC, Schadendorf D.

Eur J Cancer. 2017 Sep;83:142-145. doi: 10.1016/j.ejca.2017.06.020. Epub 2017 Jul 20. No abstract available.

PMID:
28735071
12.

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.

Scholz SL, Möller I, Reis H, Süßkind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. doi: 10.1167/iovs.17-21838.

PMID:
28700778
13.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A.

Nat Commun. 2017 May 31;8:15440. doi: 10.1038/ncomms15440.

14.

Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors.

van de Nes JAP, Koelsche C, Gessi M, Möller I, Sucker A, Scolyer RA, Buckland ME, Pietsch T, Murali R, Schadendorf D, Griewank KG.

J Invest Dermatol. 2017 Sep;137(9):2033-2035. doi: 10.1016/j.jid.2017.04.022. Epub 2017 May 10. No abstract available.

15.

SF3B1 and BAP1 mutations in blue nevus-like melanoma.

Griewank KG, Müller H, Jackett LA, Emberger M, Möller I, van de Nes JA, Zimmer L, Livingstone E, Wiesner T, Scholz SL, Cosgarea I, Sucker A, Schimming T, Hillen U, Schilling B, Paschen A, Reis H, Mentzel T, Kutzner H, Rütten A, Murali R, Scolyer RA, Schadendorf D.

Mod Pathol. 2017 Jul;30(7):928-939. doi: 10.1038/modpathol.2017.23. Epub 2017 Apr 14.

16.

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.

Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A.

Oncotarget. 2017 Jun 20;8(25):40683-40692. doi: 10.18632/oncotarget.16542.

17.

IRF4 rs12203592 functional variant and melanoma survival.

Potrony M, Rebollo-Morell A, Giménez-Xavier P, Zimmer L, Puig-Butille JA, Tell-Marti G, Sucker A, Badenas C, Carrera C, Malvehy J, Schadendorf D, Puig S.

Int J Cancer. 2017 Apr 15;140(8):1845-1849. doi: 10.1002/ijc.30605. Epub 2017 Feb 6.

18.

Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi.

Möller I, Murali R, Müller H, Wiesner T, Jackett LA, Scholz SL, Cosgarea I, van de Nes JA, Sucker A, Hillen U, Schilling B, Paschen A, Kutzner H, Rütten A, Böckers M, Scolyer RA, Schadendorf D, Griewank KG.

Mod Pathol. 2017 Mar;30(3):350-356. doi: 10.1038/modpathol.2016.201. Epub 2016 Dec 9.

19.

Oncogene Status of an Interdigitating Dendritic Cell Sarcoma: Recurrent Mutations in NF1, TP53, and ARID2 Shared With Melanoma.

Hillen U, Grabellus F, Franklin C, Sucker A, Schadendorf D, Schilling B.

Am J Surg Pathol. 2016 Dec;40(12):1721-1723. No abstract available.

PMID:
27680605
20.

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA.

Stiller M, Sucker A, Griewank K, Aust D, Baretton GB, Schadendorf D, Horn S.

Oncotarget. 2016 Sep 13;7(37):59115-59128. doi: 10.18632/oncotarget.10827.

21.

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency.

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Cancer Res. 2016 Aug 1;76(15):4347-58. doi: 10.1158/0008-5472.CAN-16-0008. Epub 2016 Jun 3.

22.

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.

Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, Pawelec G, Garbe C, Weide B.

Clin Cancer Res. 2016 Oct 1;22(19):4848-4858. Epub 2016 May 11.

23.

Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival.

Potrony M, Carreras E, Aranda F, Zimmer L, Puig-Butille JA, Tell-Martí G, Armiger N, Sucker A, Giménez-Xavier P, Martínez-Florensa M, Carrera C, Malvehy J, Schadendorf D, Puig S, Lozano F.

Int J Cancer. 2016 Sep 15;139(6):1297-302. doi: 10.1002/ijc.30184. Epub 2016 May 31.

24.

Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature.

van de Nes J, Wrede K, Ringelstein A, Stiller M, Horn S, Sucker A, Möller I, Scholz SL, Murali R, Gessi M, Schadendorf D, Griewank KG.

J Invest Dermatol. 2016 Jul;136(7):1526-1528. doi: 10.1016/j.jid.2016.03.031. Epub 2016 Apr 7. No abstract available.

25.

Oncogene status as a diagnostic tool in ocular and cutaneous melanoma.

Griewank KG, Schilling B, Scholz SL, Metz CH, Livingstone E, Sucker A, Möller I, Reis H, Franklin C, Cosgarea I, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zimmer L.

Eur J Cancer. 2016 Apr;57:112-7. doi: 10.1016/j.ejca.2016.01.010. Epub 2016 Feb 23.

PMID:
26918736
26.

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.

Xie H, Rachakonda PS, Heidenreich B, Nagore E, Sucker A, Hemminki K, Schadendorf D, Kumar R.

Oncotarget. 2016 Mar 29;7(13):16490-504. doi: 10.18632/oncotarget.7503.

27.

High mobility group box 1 is increased in the sera of psoriatic patients with disease progression.

Bergmann C, Strohbuecker L, Lotfi R, Sucker A, Joosten I, Koenen H, Körber A.

J Eur Acad Dermatol Venereol. 2016 Mar;30(3):435-41. doi: 10.1111/jdv.13564. Epub 2016 Feb 2.

PMID:
26834049
28.

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.

Willmes C, Kumar R, Becker JC, Fried I, Rachakonda PS, Poppe LM, Hesbacher S, Schadendorf D, Sucker A, Schrama D, Ugurel S.

Oncotarget. 2016 Mar 1;7(9):10117-32. doi: 10.18632/oncotarget.6956.

29.

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, Pawelec G, Garbe C, Weide B.

Clin Cancer Res. 2016 Jun 15;22(12):2908-18. doi: 10.1158/1078-0432.CCR-15-2412. Epub 2016 Jan 19.

30.

Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.

van de Nes J, Gessi M, Sucker A, Möller I, Stiller M, Horn S, Scholz SL, Pischler C, Stadtler N, Schilling B, Zimmer L, Hillen U, Scolyer RA, Buckland ME, Lauriola L, Pietsch T, Waha A, Schadendorf D, Murali R, Griewank KG.

J Neurooncol. 2016 May;127(3):435-44. doi: 10.1007/s11060-015-2052-2. Epub 2016 Jan 7.

31.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D.

Eur J Cancer. 2015 Dec;51(18):2792-9. doi: 10.1016/j.ejca.2015.08.022. Epub 2015 Nov 19.

32.

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.

Murali R, Chandramohan R, Möller I, Scholz SL, Berger M, Huberman K, Viale A, Pirun M, Socci ND, Bouvier N, Bauer S, Artl M, Schilling B, Schimming T, Sucker A, Schwindenhammer B, Grabellus F, Speicher MR, Schaller J, Hillen U, Schadendorf D, Mentzel T, Cheng DT, Wiesner T, Griewank KG.

Oncotarget. 2015 Nov 3;6(34):36041-52. doi: 10.18632/oncotarget.5936.

33.

The proteasome immunosubunits, PA28 and ER-aminopeptidase 1 protect melanoma cells from efficient MART-126-35 -specific T-cell recognition.

Keller M, Ebstein F, Bürger E, Textoris-Taube K, Gorny X, Urban S, Zhao F, Dannenberg T, Sucker A, Keller C, Saveanu L, Krüger E, Rothkötter HJ, Dahlmann B, Henklein P, Voigt A, Kuckelkorn U, Paschen A, Kloetzel PM, Seifert U.

Eur J Immunol. 2015 Dec;45(12):3257-68. doi: 10.1002/eji.201445243. Epub 2015 Oct 19.

34.

Phenotypic characterization and prognostic impact of circulating γδ and αβ T-cells in metastatic malignant melanoma.

Wistuba-Hamprecht K, Di Benedetto S, Schilling B, Sucker A, Schadendorf D, Garbe C, Weide B, Pawelec G.

Int J Cancer. 2016 Feb 1;138(3):698-704. doi: 10.1002/ijc.29818. Epub 2015 Sep 18.

35.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, Mohr P, Gutzmer R, Dummer R, Gabriel S, Wu CJ, Schadendorf D, Garraway LA.

Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10. Erratum in: Science. 2015 Nov 13;350(6262):aad8366. Science. 2016 Apr 15;352(6283). pii: aaf8264. doi: 10.1126/science.aaf8264.

36.

Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.

Scholz SL, Thomasen H, Reis H, Möller I, Darawsha R, Müller B, Dekowski D, Sucker A, Schilling B, Schadendorf D, Steuhl KP, Paschen A, Westekemper H, Meller D, Griewank KG.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5854-61. doi: 10.1167/iovs.15-17469.

PMID:
26348634
37.

Analysis of SDHD promoter mutations in various types of melanoma.

Scholz SL, Horn S, Murali R, Möller I, Sucker A, Sondermann W, Stiller M, Schilling B, Livingstone E, Zimmer L, Reis H, Metz CH, Zeschnigk M, Paschen A, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG.

Oncotarget. 2015 Sep 22;6(28):25868-82. doi: 10.18632/oncotarget.4665.

38.

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V.

Clin Cancer Res. 2015 Dec 15;21(24):5453-9. doi: 10.1158/1078-0432.CCR-15-0676. Epub 2015 Aug 19.

39.

Deciphering the genetic evolution of T-cell resistance in melanoma.

Sucker A, Paschen A.

Oncoimmunology. 2015 Feb 3;4(5):e1005510. eCollection 2015 May.

40.

Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks.

Ahmad-Nejad P, Duda A, Sucker A, Werner M, Bronsert P, Stickeler E, Reifenberger G, Malzkorn B, Oberländer M, Habermann JK, Bruch HP, Linnebacher M, Schadendorf D, Neumaier M.

Clin Chem Lab Med. 2015 Nov;53(12):1927-34. doi: 10.1515/cclm-2014-1202.

PMID:
26053008
41.

Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort.

Nsengimana J, Laye J, Filia A, Walker C, Jewell R, Van den Oord JJ, Wolter P, Patel P, Sucker A, Schadendorf D, Jönsson GB, Bishop DT, Newton-Bishop J.

Oncotarget. 2015 May 10;6(13):11683-93.

42.

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients.

Schrama D, Ugurel S, Sucker A, Ritter C, Zapatka M, Schadendorf D, Becker JC.

Front Med (Lausanne). 2014 Nov 28;1:47. doi: 10.3389/fmed.2014.00047. eCollection 2014.

43.

Genetic evolution of T-cell resistance in the course of melanoma progression.

Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maβen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A.

Clin Cancer Res. 2014 Dec 15;20(24):6593-604. doi: 10.1158/1078-0432.CCR-14-0567. Epub 2014 Oct 7.

44.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D.

J Natl Cancer Inst. 2014 Sep 13;106(9). pii: dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep.

45.

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma.

Zelba H, Weide B, Martens A, Derhovanessian E, Bailur JK, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries J, Sucker A, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Aug 15;20(16):4390-9. doi: 10.1158/1078-0432.CCR-14-1015. Epub 2014 Jun 17.

46.

Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.

Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, Cerwenka A.

Cancer Res. 2014 Jul 1;74(13):3429-40. doi: 10.1158/0008-5472.CAN-13-3017. Epub 2014 Apr 29.

47.

Inherited variation in the PARP1 gene and survival from melanoma.

Davies JR, Jewell R, Affleck P, Anic GM, Randerson-Moor J, Ozola A, Egan KM, Elliott F, García-Casado Z, Hansson J, Harland M, Höiom V, Jian G, Jönsson G, Kumar R, Nagore E, Wendt J, Olsson H, Park JY, Patel P, Pjanova D, Puig S, Schadendorf D, Sivaramakrishna Rachakonda P, Snowden H, Stratigos AJ, Bafaloukos D, Ogbah Z, Sucker A, Van den Oord JJ, Van Doorn R, Walker C, Okamoto I, Wolter P, Barrett JH, Timothy Bishop D, Newton-Bishop J.

Int J Cancer. 2014 Oct 1;135(7):1625-33. doi: 10.1002/ijc.28796. Epub 2014 Mar 6.

48.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D; DeCOG.

Ann Oncol. 2014 Mar;25(3):747-53. doi: 10.1093/annonc/mdt587. Epub 2014 Feb 6.

49.

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.

Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Büttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Mar 15;20(6):1601-9. doi: 10.1158/1078-0432.CCR-13-2508. Epub 2013 Dec 9.

50.

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, McKenna A, Cibulskis K, Farlow D, Zimmer L, Hillen U, Gutzmer R, Goldinger SM, Ugurel S, Gogas HJ, Egberts F, Berking C, Trefzer U, Loquai C, Weide B, Hassel JC, Gabriel SB, Carter SL, Getz G, Garraway LA, Schadendorf D; Dermatologic Cooperative Oncology Group of Germany (DeCOG).

Cancer Discov. 2014 Jan;4(1):94-109. doi: 10.1158/2159-8290.CD-13-0617. Epub 2013 Nov 21.

Supplemental Content

Loading ...
Support Center